Vertex Pharmaceuticals Inc
VRTX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000875320
No open-market purchases or sales by Vertex Pharmaceuticals Inc insiders were filed in the last 90 days; 1,770 institutions reported holding it in 13F filings for Q2 2026, worth $119.7B in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 5, 2026, 12:07 AM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 12, 2026 | Feb 10, 2025 | Feb 5, 2024 | Feb 7, 2023 | Jan 26, 2022 |
| Revenue | $12.0B | $11.0B | $9.87B | $8.93B | $7.57B |
| Cost of revenue | $1.65B | $1.53B | $1.26B | $1.08B | $904.2M |
| Research and development | $3.91B | $3.63B | $3.16B | $2.54B | $3.05B |
| Selling, general and administrative | $1.75B | $1.46B | $1.14B | $944.7M | $840.1M |
| Operating income | $4.17B | -$232.9M | $3.83B | $4.31B | $2.78B |
| Income tax | $690.0M | $784.1M | $760.2M | $910.4M | $388.3M |
| Net income | $3.95B | -$535.6M | $3.62B | $3.32B | $2.34B |
| EPS, basic | $15.46 | $-2.08 | $14.05 | $12.97 | $9.09 |
| EPS, diluted | $15.32 | $-2.08 | $13.89 | $12.82 | $9.01 |
| Weighted shares, basic | 255.7M | 257.9M | 257.7M | 256.1M | 257.7M |
| Weighted shares, diluted | 258.0M | 257.9M | 260.5M | 259.1M | 259.9M |
| Margins and growth | |||||
| Operating margin | 34.8% | -2.1% | 38.8% | 48.2% | 36.7% |
| Net margin | 32.9% | -4.9% | 36.7% | 37.2% | 30.9% |
| Revenue growth, year over year | +8.9% | +11.7% | +10.5% | +17.9% | +22.1% |
| Net income growth, year over year | – | −114.8% | +9.0% | +41.8% | −13.6% |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 12, 2026 | Feb 10, 2025 | Feb 5, 2024 | Feb 7, 2023 | Jan 26, 2022 |
| Cash and equivalents | $5.08B | $4.57B | $10.4B | $10.5B | $6.79B |
| Short-term investments | $1.52B | $1.55B | $849.2M | $274.5M | $729.9M |
| Accounts receivable | $2.05B | $1.61B | $1.56B | $1.44B | $1.14B |
| Inventory | $1.69B | $1.21B | $738.8M | $460.6M | $353.1M |
| Total current assets | $11.2B | $9.60B | $14.1B | $13.2B | $9.56B |
| Goodwill | $1.09B | $1.09B | $1.09B | $1.09B | $1.00B |
| Intangible assets | $424.2M | $825.9M | $839.9M | $603.6M | $400.0M |
| Total assets | $25.6B | $22.5B | $22.7B | $18.2B | $13.4B |
| Accounts payable | $461.7M | $413.0M | $364.9M | $303.9M | $195.0M |
| Total current liabilities | $3.86B | $3.56B | $3.55B | $2.74B | $2.14B |
| Total liabilities | $6.98B | $6.12B | $5.15B | $4.24B | $3.33B |
| Shareholders' equity | $18.7B | $16.4B | $17.6B | $13.9B | $10.1B |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 12, 2026 | Feb 10, 2025 | Feb 5, 2024 | Feb 7, 2023 | Jan 26, 2022 |
| Operating cash flow | $3.63B | -$492.6M | $3.54B | $4.13B | $2.64B |
| Capital expenditures | $437.6M | $297.7M | $200.4M | $204.7M | $235.0M |
| Free cash flow | $3.19B | -$790.3M | $3.34B | $3.93B | $2.41B |
| Depreciation and amortization | $209.8M | $207.2M | $181.3M | $148.3M | $125.6M |
| Stock-based compensation | $685.9M | $698.5M | $581.2M | $491.3M | $441.4M |
| Share buybacks | $2.02B | $1.18B | $427.6M | $0 | $1.43B |
| Investing cash flow | -$945.4M | -$3.77B | -$3.14B | -$321.1M | -$340.9M |
| Financing cash flow | -$2.26B | -$1.49B | -$562.2M | -$67.7M | -$1.48B |
| Net change in cash | $515.6M | -$5.80B | -$139.7M | $3.71B | $811.2M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 5.7% | 6.3% | 5.9% | 5.5% | 5.8% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Oct 31, 2026 | 253.5M | −0.1% | SEC |
| Jul 31, 2026 | 253.5M | −1.1% | SEC |
| Apr 30, 2026 | 253.8M | −1.2% | SEC |
| Feb 6, 2026 | 254.0M | −1.1% | SEC |
| Oct 31, 2025 | 253.7M | −1.5% | SEC |
| Jul 31, 2025 | 256.4M | −0.7% | SEC |
| Apr 30, 2025 | 256.8M | −0.5% | SEC |
| Feb 7, 2025 | 256.8M | −0.6% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.